Clinical Trials
14 trialsNCT00569127 2026-05-26
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01274338 2026-05-05
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02506153 2026-05-04
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
NCT00204529 2017-05-03
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
University Hospital Tuebingen
Phase 3 Completed
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01609010 2014-09-08
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT00502034 2013-07-10
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Completed
NCT00416429 2012-09-26
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00083889 2010-01-26
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
Phase 3 Completed
NCT00483132 2007-06-06
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
French Innovative Leukemia Organisation
Phase 3 Completed